A multicentre, randomized, double-blinding, cross-over controlled trial of the effectiveness and safety of TES pollen blockers in patients with seasonal and perennial allergic rhinitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17013838

Enrollment

Unknown

Registered

2017-12-12

Start date

2011-09-01

Completion date

Unknown

Last updated

2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rhinitis

Interventions

Control:placebo

case:pollen blocker

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 6 to 60 years and diagnosed with at least 1 year of perennial AR (confirmed by clinical history, positive skin-prick tests, and serum-specific immunoglobulin E of 0.7 kU/L), with an average total nasal symptom score (TNSS) of at least 20 during the week were included in the study

Exclusion criteria

Exclusion criteria: Exclusion criteria included known hypersensitivity to ingredients in the product under investigation, severe septum deviation, nasal polyps, participation in other clinical trials within the preceding 30 days, concomitant disease that could affect the variables assessed in this study to such an extent that an objective judgment would not be possible, and women of childbearing age who are not using sufficient contraception.

Design outcomes

Primary

Measure	Time frame
syndrome;	—

Countries

China

Contacts

Public ContactDehui Wang

EENT Hospital of Fudan University

wangdehuient@sina.com+86 021-64377134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026